Enable Injections promotes COO from within

Wearable drug delivery technology maker Enable Injections announced today that it named David Kroekel as […]

Wearable drug delivery technology maker Enable Injections announced today that it named David Kroekel as its new COO.

Cincinnati-based Enable develops the enFuse platform, whichallows hands-free, hidden needle drug delivery of up to 25 mL. Its simple design enables flexibility for at-home self-administration or in-clinic use. The FDA cleared the system for the delivery of Empaveli in October.

Previously, Kroekel served as SVP of product development and operations. As COO, his role includes leading the ongoing engineering, manufacturing and supply of enFuse technology.

“David brings a wealth of experience in cross-functional collaboration, infrastructure development, and engineering excellence in medical device manufacturing and development,” said Mike Hooven, chair and CEO of Enable Injections. “In the past year, Enable has poised itself for long-term commercial success and increasing product demand. David’s leadership at Enable has played a pivotal role in our company’s success to date and we are excited to have him in this new position as COO as we continue driving innovation for enFuse and bringing this game-changing technology to our partners, HCPs, and most importantly – patients.”

More about new Enable Injections COO David Kroekel

Kroekel has more than 35 years in the medical device industry, including combination product operations and product development. He previously served as biomedical global head of operations at DSM Biomedical. Before DSM, he held a number of senior positions at companies including Flowonix, Teleflex and Arrow.

“As the first-ever hands-free wearable technology that allows patients to self-administer large-volume medications without an IV or syringe pump, enFuse is a breakthrough in meeting patient needs with new and innovative solutions,” Kroekel said. “I look forward to leading and advancing how our manufacturing and product development teams increase the capabilities and efficiencies in delivering our wearable technology to more patients.”

Enable currently has plans to work with more pharma partners to conduct clinical trials. It aims to plan for the joint commercial launch of therapies in combination with enFuse.

Original Article: (https://www.drugdeliverybusiness.com/enable-injections-promotes-coo-from-within/)